Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Halozyme ( (HALO) ) has issued an update.
On November 6, 2025, Halozyme Therapeutics announced the pricing of $650 million in convertible senior notes due 2031 and another $650 million due 2032. The company plans to use the proceeds to fund capped call transactions and repurchase existing convertible notes, which could impact the market price of its common stock and reduce potential dilution upon conversion.
The most recent analyst rating on (HALO) stock is a Buy with a $92.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.
Spark’s Take on HALO Stock
According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.
Halozyme’s strong financial performance and positive earnings call are the primary drivers of its high score. The company’s robust revenue growth and raised guidance reflect confidence in its strategic direction. Technical analysis presents mixed signals, and while the valuation is reasonable, high leverage remains a risk.
To see Spark’s full report on HALO stock, click here.
More about Halozyme
Halozyme Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing innovative therapies. The company’s primary products and services include drug delivery platforms and proprietary enzymes, with a market focus on enhancing the delivery of biologics and small molecules.
Average Trading Volume: 2,015,536
Technical Sentiment Signal: Strong Buy
Current Market Cap: $8.03B
For an in-depth examination of HALO stock, go to TipRanks’ Overview page.